A translational study [21] evaluating gastric cancer samples of the GATSBY trial [17] demonstrated more benefit to T-DM1 in terms of PFS in patients with tumors with higher ERBB2 mRNA levels [21]. Here, ERBB2 is linked to gastric cancer.